• Opaleye Management, a 10% owner of Eton Pharmaceuticals, reported selling 28,315 common shares on July 14.
• Sales priced at a weighted average of USD 37.54 per share.
• Beneficial ownership fell to 2.67 million shares held via Opaleye, L.P.
• Separate managed-account holdings declined to 40,000 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033577), on July 16, 2026, and is solely responsible for the information contained therein.